What is Immunos Therapeutics?
Founded in 2014, ImmunOs Therapeutics specializes in the discovery and development of human immunomodulatory proteins that modulate both innate and adaptive immune responses. The company operates at the intersection of advanced immunology and drug development, focusing on proteins that can be harnessed to treat complex, life-threatening conditions. By targeting the fundamental mechanisms of the immune system, ImmunOs aims to create a new class of therapeutics that offer superior efficacy and safety profiles compared to existing standards of care. Its strategic focus on high-impact, innovative assets has positioned it as a critical entity within the European biotech ecosystem, drawing support from specialized venture capital firms and industry incumbents alike.
How much funding has Immunos Therapeutics raised?
Immunos Therapeutics has raised a total of $99.2M across 3 funding rounds:
Series A
$15.2M
Series B
$73M
Series C
$11M
Series A (2019): $15.2M with participation from Redalpine, BERNINA BioInvest Ltd, Schroder Adveq, Wille Finance AG, Pfizer Ventures, and BioMedPartners
Series B (2022): $73M, investors not publicly disclosed
Series C (2024): $11M supported by Mission BioCapital, BioMedPartners, Pfizer, and Gimv
Key Investors in Immunos Therapeutics
Redalpine
A thesis-driven venture capital firm established in 2006 that specializes in supporting highly technical companies within the software and science sectors.
Schroder Adveq
A leading global asset manager with extensive experience in private equity, providing long-term strategic support to innovative companies across various sectors.
BioMedPartners
An independent Swiss-based venture capital firm focused on building early-stage biotech companies with highly innovative technology platforms and strong entrepreneurial teams.
What's next for Immunos Therapeutics?
With the recent influx of capital, ImmunOs Therapeutics is well-positioned to advance its clinical programs and expand its research capabilities. The strategic focus will likely center on the maturation of its lead candidates, optimizing its protein engineering platform, and potentially exploring new therapeutic indications. As the company transitions further into its clinical-stage lifecycle, the emphasis will shift toward data generation and regulatory milestones, which are essential for long-term value creation. The continued backing from experienced life science investors suggests a high degree of confidence in the company's ability to navigate the complexities of drug development and deliver transformative medical breakthroughs to patients globally.
See full Immunos Therapeutics company page
